Article Text
Statistics from Altmetric.com
Clindamycin seems to be being used more frequently (just an anecdotal observation). The Archivist has always held clindamycin in reserve for careful use as an adjuvant to using β-lactam antibiotics for the more severe group A β-haemolytic streptococcal invasive infections (iGAS) such as necrotising fasciitis. Is there good evidence of a benefit in the use of clindamycin in treating patients with invasive non-group A/B β-haemolytic streptococcal (iNABS) infections? Babiker A et al. [Lancet Infectious Dis 2021 https://doi.org/10.1016/ S1473-3099(20)30523-5] have published the findings of a retrospective multicentre cohort study, using a dataset from adult patients in an …
Footnotes
Provenance and peer review Commissioned; internally peer reviewed.